You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results
IMpower133 trial was a Phase III study of first-line atezolizumab + carboplatin and etoposide vs placebo + carboplatin and etoposide in patients with ES-SCLC. This presentation reports patient outcomes from the Phase IV, single-arm IMbrella A extension and long-term observational study as an extension of the IMpower133 results.
Request medical material
Would you like to receive this poster via email to view later?